Free Trial
Eva Fortea-Verdejo

Eva Fortea-Verdejo Analyst Performance

Biotech equity research analyst at Wells Fargo & Company

Eva Fortea-Verdejo is a stock analyst at Wells Fargo & Company in the medical sector, covering 3 publicly traded companies. Over the past year, Eva Fortea-Verdejo has issued 3 stock ratings, including buy and hold recommendations. While full access to Eva Fortea-Verdejo's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Eva Fortea-Verdejo's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
3 Last 0 Years
Buy Recommendations
66.67% 2 Buy Ratings
Companies Covered
3 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy66.7%2 ratings
Hold33.3%1 ratings
Sell0.0%0 ratings

Out of 3 total stock ratings issued by Eva Fortea-Verdejo at Wells Fargo & Company, the majority (66.7%) have been Buy recommendations, followed by 33.3% Hold.

Best & Worst Calls

This analyst does not have any ratings with enough history to determine best and worst calls.

Exchange Coverage

ExchangePercentageCount
NASDAQ
66.7% of companies on NASDAQ
2 companies
NYSE
33.3% of companies on NYSE
1 company

Eva Fortea-Verdejo, an analyst at Wells Fargo & Company, currently covers 3 companies listed on NASDAQ and NYSE, with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Medical
3 companies
100.0%

Eva Fortea-Verdejo of Wells Fargo & Company specializes in stock coverage within the Medical sector.

Coverage Industries

IndustryPercentage
MED - BIOMED/GENE
2 companies
66.7%
MED - DRUGS
1 company
33.3%

Eva Fortea-Verdejo's Ratings History at Wells Fargo & Company

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
iTeos Therapeutics, Inc. stock logo
ITOS
iTeos Therapeutics
8/7/2025Lower Price Target$10.13$11.00Equal Weight
Xencor, Inc. stock logo
XNCR
Xencor
8/7/2025Lower Price Target$7.19$27.00Overweight
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
8/7/2025Lower Price Target$9.35$25.00Overweight